Guided Therapeutics Q3: $111K Cash, Going Concern, Material Weaknesses, New $0.20 Tranche
GTHP is trading near its 52-week low of $0.1 (10.0% above the low) on light trading volume (0.1× avg).
Summary
Guided Therapeutics reported a $2.3 million nine-month loss with only $111 thousand of cash, reiterated going concern, disclosed material weaknesses in internal controls, and opened a new $0.20 per unit private placement tranche while its $1.1 million convertible debenture remains in default.
Key Events · Earnings and Guidance · GTHP
-
Q3 Loss and Thin Cash Balance
Net loss attributable to common stockholders was $2.3 million for the nine months ended September 30, 2026, with cash of only $111 thousand versus a working capital deficit of approximately $6.2 million.
-
Going Concern Reiterated
Accumulated deficit reached $159.4 million and stockholders' deficit $6.1 million; management states substantial doubt about the ability to continue as a going concern and may curtail operations or liquidate if capital cannot be raised.
-
Material Weaknesses Disclosed
Disclosure controls were ineffective at September 30, 2026 due to material weaknesses from insufficient resources for complex transactions and lack of board/audit committee oversight, including documented approval of related-party transactions.
-
Debenture Still in Default
The $1.1 million 10% senior convertible debenture matured May 17, 2024 and remains unpaid, accruing 18% default interest; total arrearage was about $1.4 million including $258 thousand of accrued interest.
Analysis · GTHP · Industrial Applications And Services
Guided Therapeutics ended September 30, 2026 with just $111 thousand of cash against a $6.2 million working capital deficit and a $159.4 million accumulated deficit, and management again states substantial doubt about its ability to continue as a going concern. The company also disclosed that its disclosure controls were ineffective because of material weaknesses in internal control over financial reporting, including a lack of board and audit committee oversight of significant and related-party transactions. Funding is coming from a rolling private placement: $480 thousand raised in the first nine months, a new $0.20 per unit tranche (up to 5,000,000 shares plus 7,500,000 warrants) that had drawn $100 thousand, and post-quarter subscriptions of $150 thousand plus a $500 thousand subscription that had not yet closed. Against that, the $1.1 million 10% convertible debenture has been in default since May 17, 2024 and now accrues 18% interest, with total arrearage of about $1.4 million. The FDA PMA clinical module was filed June 15, 2026 and the $145 thousand small-business user fee was paid September 28, 2026, so an FDA decision is the main swing factor; without new capital the company says it may have to curtail operations or liquidate.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GTHP was trading at $0.11 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $10.6M. The 52-week trading range was $0.10 to $0.54. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.